Physician profile
Thanh Le
NPI 1144664384
$1,084.62
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $309 · 2021: $435 · 2022: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $175.26 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $159.31 | 2019-2022 | |
| Abbvie INC. | $149.18 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.91 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $96.88 | 2020-2022 | |
| Allergan, INC. | $87.95 | 2019-2020 | |
| Glaxosmithkline, LLC. | $61.25 | 2020 | |
| Alnylam Pharmaceuticals INC. | $38.41 | 2021 | |
| Abbott Laboratories | $37.04 | 2021-2022 | |
| Genentech USA, INC. | $33.07 | 2020 | |
| Amgen INC. | $22.23 | 2020 | |
| Amarin Pharma, INC. | $18.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.55 | 2020 | |
| Lilly USA, LLC | $17.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.34 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.41 | 2020 | |
| Astellas Pharma US INC | $13.86 | 2019 | |
| Ermi LLC | $11.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thanh Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.